


PRODUCT INFORMATION



SU 6668

Item No. 13873

CAS Registry No.: 252916-29-3
Formal Name: 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-propanoic acid
Synonyms: NSC 702827 Orantinib TSU-68
MF: C₁₈H₁₈N₂O₃
FW: 310.4
Purity: ≥98%
UV/Vis.: λ_{max}: 212, 279, 447 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

SU 6668 is supplied as a crystalline solid. A stock solution may be made by dissolving the SU 6668 in the solvent of choice, which should be purged with an inert gas. SU 6668 is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of SU 6668 in these solvents is approximately 2.5 and 5 mg/ml, respectively.

SU 6668 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, SU 6668 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. SU 6668 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

SU 6668 is an inhibitor of the receptor tyrosine kinases PDGFRβ, VEGFR2, and FGFR1 (IC₅₀ = 0.06, 2.4, and 3.0 μM, respectively) but not EGFR (IC₅₀ >100 μM).^{1,2} Through these actions, SU 6668 suppresses tumor growth, blocks angiogenesis in tumors, and induces apoptosis of tumor vasculature and regression of established tumors.³⁻⁵ It also inhibits metastasis in a mouse orthotopic model of melanoma.⁶ SU 6668 also inhibits Aurora kinases B and C (IC₅₀ = 35 and 210 nM, respectively) and may target other kinases.^{7,8}

References

1. Sun, L., Tran, N., Liang, C., *et al.* *J. Med. Chem.* **42**(25), 5120-5130 (1999).
2. Kammasud, N., Boonyarat, C., Sanphanya, K., *et al.* *Bioorg. Med. Chem. Lett.* **19**(3), 745-750 (2009).
3. Laird, A.D., Vajkoczy, P., Shawver, L.K., *et al.* *Cancer Res.* **60**(15), 4152-4160 (2000).
4. Griffin, R.J., Williams, B.W., Wild, R., *et al.* *Cancer Res.* **62**(6), 1702-1706 (2002).
5. Laird, A.D., Christensen, J.G., Li, G., *et al.* *FASEB J.* **16**(7), 681-690 (2002).
6. Gangjee, A., Kurup, S., Ilnat, M.A., *et al.* *Bioorg. Med. Chem.* **18**(10), 3575-3587 (2010).
7. Godl, K., Gruss, O.J., Eickhoff, J., *et al.* *Cancer Res.* **65**(15), 6919-6926 (2005).
8. Bain, J., Plater, L., Elliot, M., *et al.* *Biochem. J.* **408**(3), 297-315 (2007).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/04/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM